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Introduction
Joint trauma leads to acute posttraumatic arthritis and in 
the majority of individuals, as a long-term complication, 
to osteoarthritis (OA) [1]. Th   ere are an estimated 900,000 
cases of knee injuries annually in the United States, and 
posttraumatic OA accounts for 12% of all cases of OA [2]. 
In some joints, such as the ankle, OA predominantly 
develops after joint trauma [2]. As posttraumatic OA 
primarily aﬀ   ects younger individuals [3,4], it leads to 
reduced physical activity and to deconditioning of the 
musculoskeletal system. Joint replacement in this young 
patient group is complicated by the limited lifespan of the 
implants.
OA risk increases with patient age at the time of injury 
and with time from the onset of injury [4,5]. Th  e  presence 
of additional OA risk factors, such as obesity, joint 
malalignment or genetic risk factors, leads to a more 
severe outcome. Between 60 and 80% of patients with 
magnetic resonance imaging or arthroscopically docu-
mented cartilage injury developed cartilage degeneration 
within 5 years [6,7]. Patients with anterior cruciate liga-
ment (ACL)-deﬁ  cient knees, with or without a concomi-
tant meniscus injury, are at high risk for posttraumatic 
OA [5,8]. Previous concepts that residual joint instability 
after ACL reconstruction is the cause of OA have not been 
conﬁ  rmed as OA develops in joints with ACL injuries even 
if reconstructive surgery successfully nor  mal  izes joint 
biomechanics. Th   ese observations empha  size the role of 
events in the time period after the initial joint trauma.
Joint trauma aﬀ  ects all joint tissues to some degree but 
the damage to articular cartilage appears most signiﬁ  cant, 
as it is largely irreversible and may be the major deter-
minant for the subsequent development of OA. Th   ere is a 
certain degree of immediate or irreversible damage, but 
the days and weeks after injury represent the phase where 
damage progresses most rapidly. Th  e acute symptoms 
following joint injury include joint pain and swelling due 
to intraarticular bleeding, synovial eﬀ  usion and inﬂ  am-
ma  tory cell inﬁ  ltration. Patients typically undergo surgical 
treatment of the ligament and meniscus lesions within 
3 months after the initial injury [2]. Currently there are 
no approved therapies to address acute posttraumatic 
arthritis. Corticosteroids have potent anti-inﬂ  ammatory 
activity but potential beneﬁ   ts or adverse eﬀ  ects  of 
cortico  steroids in a restricted dose and frequency of 
administration for traumatic joint injury have not been 
resolved and remain to be studied.
Furthermore, measures to prevent OA are not available, 
although patients with posttraumatic arthritis represent a 
readily identiﬁ  ed population at risk for developing OA 
and thus are ideal to test preventive and therapeutic 
measures. Interventions early during the most dynamic 
postinjury phase have the potential to limit the degree of 
acute joint damage and to delay the onset and reduce the 
severity of OA. Th   e prolonged posttraumatic inﬂ  amma-
tory insult also signiﬁ  cantly increases the risk of arthro-
ﬁ  brosis for which satisfactory management remains to be 
developed. Th  e present review addresses pathogenetic 
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Joint trauma can lead to a spectrum of acute lesions, 
including osteochondral fractures, ligament or 
meniscus tears and damage to the articular cartilage. 
This is often associated with intraarticular bleeding and 
causes posttraumatic joint infl  ammation. Although the 
acute symptoms resolve and some of the lesions can 
be surgically repaired, joint injury triggers a chronic 
remodeling process in cartilage and other joint tissues 
that ultimately manifests as osteoarthritis in a majority 
of cases. The objective of the present review is to 
summarize information on pathogenetic mechanisms 
involved in the acute and chronic consequences of 
joint trauma and discuss potential pharmacological 
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events that follow joint trauma since therapies for 
posttraumatic joint infl  ammation are not available and 
this represents a unique window of opportunity to 
limit chronic consequences.
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chronic consequences of joint trauma and candidates for 
pharmacological intervention.
Pathogenetic mechanisms
Th   e pathogenetic processes can temporally be separated 
into the immediate events that are related to the 
mechanical impact, the acute posttraumatic phase with 
prominent inﬂ   ammation that can last up to approxi-
mately 2 months and the chronic phase. Subtle metabolic 
changes in cartilage and other joint structures slowly 
progress through a long clinically asymptomatic latency 
period to a symptomatic phase with joint pain and 
dysfunction. In the majority of patients this leads to a 
clinical diagnosis of OA, and in some patients ultimately 
requires joint replacement (Table 1).
Immediate eff  ects of mechanical impact
Th   e acute mechanical overload during joint trauma can 
cause bone fracture, rupture of ligaments and menisci, 
lesions in the joint capsule and synovium, and compres-
sive or shear damage to the articular cartilage. When 
cartilage is exposed to compressive and shear forces it 
can separate from the subchondral bone. Exposure to 
lower forces leads to immediate changes in cartilage cell 
viability due to necrosis, and cracks or ﬁ  ssures of the 
cartilage surface that can extend into the mid and deep 
zone, and leads to release of cartilage extracellular matrix 
molecules [9]. Compressive chondral injuries may not be 
evident at arthroscopy but are in some cases associated 
with subchondral bone marrow edema [10].
Th  e synovial ﬂ   uid is severely compromised in its 
lubricating function. Th   is is the result of dilution due to 
intraarticular bleeding and plasma extravasation, leading 
to lower concentrations of hyaluronic acid and lubricin, 
the major joint lubricants. Neutrophil-derived enzymes 
degrade lubricin, and inﬂ  ammatory mediators present in 
the posttraumatic synovial ﬂ  uid suppress the synthesis of 
lubricin [11]. In patients with ACL injury, the decrease in 
lubricin is most marked in the days after injury and 
gradually approaches near-normal levels within 1 year [11].
Th   e immediate collagen damage in cartilage is caused 
by mechanical rupture due to tensile failure [12]. 
Carti  lage swelling occurs within hours after impact as the 
swelling pressure of the glycosaminoglycans (GAGs) is 
no longer restrained by an intact collagen network [13]. 
Th   ere is also rapid GAG loss that appears to result from 
the acute physical impact since it is not prevented by 
inhibitors of GAG-degrading enzymes [14].
Following these immediate changes is the acute post-
traumatic phase, with activation of remaining viable cells 
in articular cartilage and other joint tissues that respond 
to the mechanical trauma with enhanced cell metabolism 
and the generation of oxygen radicals, matrix-degrading 
enzymes and inﬂ  ammatory mediators. Mechanical injury 
also leads to suppression of collagen and GAG synthesis. 
A recovery from this suppression and an increase of new 
matrix synthesis can occur subsequently, but this is 
compromised by the presence of the inﬂ  ammatory 
response [15].
Hemarthrosis
Rapidly developing intraarticular bleeding caused by 
rupture of blood vessels in the joint capsule, synovium, 
menisci or subchondral bone is observed in >90% of 
patients with joint trauma that have surgically signiﬁ  cant 
lesions such as osteochondral fracture, ligament or 
meniscus tears, but also occurs at lower frequency in 
patients without signiﬁ  cant acute intraarticular pathology 
[16]. Hemarthrosis is an important factor in the patho-
gene  sis of posttraumatic arthritis since even a single epi-
sode of intraarticular bleeding can lead to cartilage 
damage.
Experimental injection of autologous blood into 
normal joints causes loss of proteoglycans and inhibits 
proteoglycan synthesis [17]. In addition, exposure of 
articular cartilage in vitro to whole blood in the absence 
of other stimuli induces chondrocyte apoptosis. Neutro-
phils in acute hemarthrosis are activated and produce 
increased levels of reactive oxygen species, elastase and 
other lysosomal enzymes [18]. Extracellularly released 
elastase is a potent lysosomal enzyme that degrades 
proteoglycans. Mononuclear cells cause reversible sup-
pres  sion of GAG synthesis but this becomes irreversible 
in the presence of red blood cells. Th  is irreversible 
inhibition is independent of the cytokines IL-1 and TNF 
Table 1. Pathogenesis of posttraumatic cartilage degradation
Immediate (seconds)  Acute (months)  Chronic (years)
Cell necrosis  Apoptosis  Joint tissue remodeling
Collagen rupture  Leukocyte infi  ltration 
Glycosaminoglycan loss  Infl  ammatory mediators 
Hemarthrosis  Extracellular matrix degradation  Infl  ammation
 Defi   cient  lubricants 
 Arthrofi   brosis 
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globin degradation products such as deoxyhemoglobin, 
methemoglobin, and hemosiderin appear to mediate the 
blood-induced damage.
Hemarthrosis also leads to synovial hypertrophy and 
siderosis, due to phagocytosis of erythrocytes and 
hemoglobin by synovial cells. Synovitis develops only at 
later stages and may be triggered by mediators that result 
from cartilage damage, such as matrix degradation 
products or chondrocyte-derived cytokines [20]. Th  ere  is 
thus strong evidence that intraarticular bleeding, even a 
single episode, leads to joint damage – and intraarticular 
bleeding should therefore be addressed in the treatment 
of posttraumatic arthritis. Additional bleeding at the time 
of surgery could in itself be deleterious to cartilage health 
and could potentially recapitulate and prolong the events 
initiated by the primary trauma.
Arthrofi  brosis
Fibrogenesis resulting in clinically signiﬁ  cant  arthro-
ﬁ  brosis remains a problem due to the lack of eﬃ   cient 
preventive and therapeutic strategies [21,22]. Presently, 
clinical management of arthroﬁ  brosis emphasizes pre  ven-
tion strategies, including early passive range-of-motion 
exercises. Once ﬁ   brosis has developed, interventions 
consist of steroid injections, physical therapy and, 
ultimately, surgery for debridement. Arthrolysis surgery 
may be required more than once in some patients.
A key strategy for the prevention of arthroﬁ  brosis is to 
delay the time to ACL reconstruction surgery for an 
acute ACL tear. Th   is approach is supported by evidence 
that performing surgery within 4 weeks of ACL injury is a 
risk factor for postoperative development of arthro-
ﬁ   brosis [23]. Th  e presence of preoperative swelling, 
eﬀ  usion and hyperthermia correlated with development 
of arthroﬁ  brosis [24]. Furthermore, if joint inﬂ  ammation 
persisted after 4 weeks, the risk of arthroﬁ  brosis  re-
mained elevated. Th   ese observations suggest it is inﬂ  am-
mation, and not timing of the surgery, which predicts 
development of arthroﬁ  brosis postoperatively. Attempts 
to reduce preoperative inﬂ   ammation are therefore 
requir  ed to prevent this postsurgical complication.
Posttraumatic cartilage cell death
Cell death in cartilage has been identiﬁ  ed as an important 
mechanism in the development of OA joint pathology 
[25]. Cell death has also become a focus of research on 
posttraumatic cartilage damage and has been studied in 
vitro, in open and closed impact animal models, as well 
as in human joints.
Cell death after traumatic cartilage impact occurs in 
two phases: an immediate phase due to cell necrosis, 
followed by a subsequent spreading of cell death media-
ted by apoptotic mechanisms beyond the initial area to 
the surrounding unimpacted regions [12,26-29], leading 
to expansion of the original lesion [9]. Th  is progressive 
increase in apoptotic cells after injury oﬀ  ers a therapeutic 
window. Compressive loading of cartilage causes signiﬁ  -
cant apoptotic cell death [26,30] that develops around 
matrix cracks, and there is a linear relationship between 
impact energy and cell death [31]. Th  e cartilage super-
ﬁ  cial zone is most susceptible to cell death after mecha-
nical injury [32]. Apoptosis has been demonstrated after 
mechanical injury in animal models and in human joint 
trauma as indicated by the activation of caspases, the 
enzymes that regulate and execute apoptosis [10]. A sub-
stantial increase in apoptotic cell death in cartilage was 
also observed after intraarticular fracture in humans [33,34].
Th   e consequences of cell death are that it contributes 
to matrix degradation and depletes cartilage of the cells 
that are required to repair and maintain extracellular 
matrix. Th   e percentage of apoptotic chondrocytes corre-
lates with the level of GAG loss in the impacted tissues 
[35]. Th  is suggests that cell death contributes to matrix 
degradation and deﬁ  cient repair.
Observations on the short-term consequences of 
mechanical cartilage injury on apoptosis thus suggest 
that: in vivo chondrocyte apoptosis can be induced by a 
single impact load; the extent of apoptosis in vitro 
correlates with the intensity of the load applied and 
increases with time in culture; chondrocyte death can 
precede structural damage; caspase inhibitors reduce cell 
death, maintain functional cells and protect against 
extracellular matrix damage; and a therapeutic window 
exists where apoptosis can be inhibited.
Infl  ammatory cytokines
Cytokines in the IL-1 family are principal mediators of 
the acute posttraumatic inﬂ  ammatory response [36,37]. 
Increased IL-1 expression has been documented after 
mechanical joint injury and correlates with the severity of 
cartilage damage [38]. IL-1 is overexpressed by chondro-
cytes, synoviocytes and inﬁ  ltrating  inﬂ  ammatory  cells. 
Furthermore, synovial ﬂ  uid levels of the IL-1 receptor 
antagonist (IL-1Ra) decrease after ACL injury [39]. IL-1 
induces mediators of joint pain, and it promotes cartilage 
matrix degradation by inducing expression of extra-
cellular matrix-degrading enzymes and inhibiting extra-
cellular matrix synthesis and the anabolic activity of 
growth factors [40,41].
Th   e levels of IL-6 and TNFα in human synovial ﬂ  uid 
also increase signiﬁ   cantly after acute joint injury 
[11,42]. IL-6 with its soluble receptor potentiates the 
catabolic eﬀ  ects of TNFα in the degradation and loss of 
proteo  glycans from cartilage [43]. Furthermore, 
mechanical injury potentiates proteoglycan catabolism 
induced by this combination of TNFα and IL-6 with its 
soluble receptor [44]. Th   is provides a potential 
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following trauma.
Extracellular matrix-degrading enzymes
Release of extracellular matrix-degrading enzymes has 
been established as an important mechanism in post-
traumatic cartilage damage. Fragments of extracellular 
matrix such as collagen or ﬁ  bronectin fragments that are 
generated by these enzymes stimulate further production 
of pathogenetic mediators [45]. Th  e speciﬁ  c  enzymes, 
kinetics of release and cellular origin vary with the 
experimental model used. Studies with cartilage explants 
that are subjected to mechanical impact injury demon-
strate that the remaining viable chondrocytes express 
increased levels of matrix metalloproteinase (MMP)-1, 
MMP-3, MMP-8, MMP-9, MMP-13 and ADAM-TS5 
[46,47]. Analyses of synovial ﬂ  uid samples taken from 
patients after an ACL or meniscal tear revealed increased 
MMP-3 levels that remained elevated for many years 
[48]. Joint ﬂ   uid also showed an initial and persistent 
elevation of the neoepitope Col2CTx in the C-telopeptide 
of type II collagen, indicating digestion of mature, cross-
linked collagen by a MMP. Fragments of cartilage oligo-
meric protein and aggrecan were also elevated [49-51].
Taken together, these studies suggest that extracellular 
matrix degradation rates are signiﬁ  cantly altered within 
days of the injury and remain altered for years. Th  e  acute 
joint tissue response to the original mechanical insult 
thus seems to initiate an unbalanced degradative process 
that can signiﬁ  cantly increase the risk of OA.
Pharmacological treatment options
Th  ere is a clear recognition of the risk to develop OA 
after joint trauma, and thus there is an obvious and 
urgent need to develop and implement strategies that 
prevent posttraumatic cartilage degradation. Here we 
focus on pharmacological interventions, but these need 
to be integrated with surgery and neuromuscular–bio-
mechanical training. Research on pathogenetic mecha-
nisms has identiﬁ   ed major pathways and therapeutic 
targets. Pharmacological interventions need to inhibit 
the posttraumatic inﬂ  ammatory responses, prevent cell 
death, prevent degradation and stimulate production of 
new cartilage extracellular matrix. Th  e optimal therapy 
should address several or all of the pathogenesis path-
ways. Whether separate approaches are required to ﬁ  rst 
interfere with early catabolic and inﬂ  ammatory events 
and subsequently to promote anabolic responses, so that 
therapeutic approaches eﬀ   ectively stimulate proper 
cartilage repair at the appropriate time after trauma, 
needs to be deter  mined. Goals of therapy are to provide 
immediate and long-term beneﬁ  ts, and it is possible that 
interventions during the ﬁ  rst few months after injury can 
accomplish both. An important unanswered question is 
when and which therapies that have been developed as 
disease-modifying OA drugs [52] are indicated for 
patients with post  traumatic OA. A promising route of 
drug administration during the early phase after joint 
injury is intraarticular injection. Th   is has the advantages 
of reaching high drug concentrations at the lesion site 
with low systemic drug exposure, and thus reduced risk 
for systemic adverse events.
Animal models used to test potential therapies include 
joint damage and OA-like pathology induced by creating 
joint instability through performing ligament transection 
and/or meniscectomy. Th   ese models are associated with 
chronic or repetitive impact loading, and lead to a rapid 
develop  ment of full thickness cartilage lesions within 3 to 
8 weeks. Such models are the standard tools to evaluate 
disease-modifying OA drugs, and have been used to 
identify a large number of therapies that improve experi-
men  tal lesions. A limitation of repetitive injury as a model 
of posttraumatic OA is that it disrupts endogenous repair 
responses. Single closed-impact injuries probably repre-
sent better models of human joint trauma. Th  e closed-
impact models are performed in larger animals [53,54].
Caspase inhibitors
Evidence from in vitro and animal model studies suggests 
there is a time window after injury when cartilage cells 
can be rescued or protected from undergoing cell death, 
resulting in the maintenance of viable and functional cells 
and reducing cartilage structural damage [25]. Th  is  oﬀ  ers 
the opportunity of preventing chronic joint destruction, 
pain and disability by intraarticular administration of a 
pharmaceutical during the immediate time interval after 
joint injury. Th   e key role that caspases play in initiating 
and executing apoptosis make them prime targets for 
apoptosis modulation. Antiapoptotic agents have been 
successfully explored in models of diseases aﬀ  ecting the 
central nervous system, liver and kidneys [55-57]. Speci-
ﬁ  c to chondrocytes, a series of in vitro studies demon-
strated that caspase inhibitors are eﬀ  ective in protecting 
against chondrocyte apoptosis, maintaining viable and 
functional cells [58]. Reduction of cartilage degeneration 
following intraarticular injection of caspase inhibitor has 
also been reported for a rabbit model of OA [59].
Caspases recognize substrates with a strict requirement 
for aspartic acid. Caspase inhibitors have been developed 
on dipeptide, tripeptide and tetrapeptide scaﬀ  olds that 
represent recognition sites in caspase substrates and a 
ﬂ  uoromethylketone warhead [60]. Th   e inhibitors diﬀ  er in 
their speciﬁ  city for individual caspases, in their ability to 
penetrate into the intracellular space and in whether they 
are reversible or irreversible inhibitors. In addition to the 
role of caspases in the regulation and execution of cell 
death, caspase 1 (also termed IL-converting enzyme) is 
responsible for converting the precursors of IL-1 family 
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ceu  ticals that inhibit IL-converting enzyme/caspase-1 
thus have potential to neutralize the pathogenic eﬀ  ects of 
IL-1 family cytokines [61].
Chemical caspase inhibitors are available that are 
speciﬁ  c for individual caspases or neutralize the activity 
of all caspases. Such pan-caspase inhibitors would be 
ideally suited to be eﬀ  ective as interventions for the acute 
posttraumatic inﬂ  ammation and to limit cell and cartilage 
damage. Th  e pan-caspase inhibitor z-VAD.fmk is a 
prototype compound that has been used extensively in 
vitro and in animal models for proof-of-concept studies. 
Inhibitors of speciﬁ   c caspases as well as pan-caspase 
inhibitors were tested in various models, and pan-caspase 
inhibitors appeared to be most potent in reducing 
chondrocyte apoptosis and GAG release [62,63]. A 
similar compound – a dipeptide-based, irreversible, cell-
permeable and broad-spectrum caspase inhibitor [64] – 
was evaluated in the treatment of liver disease and results 
from phase II clinical trials were published [65]. Th  e  drug 
showed no adverse eﬀ  ects and improved markers of liver 
damage in patients with chronic hepatitis C virus 
infection [65]. Proof-of-concept has thus been 
established for caspase inhibition as an eﬀ  ective therapy 
for diseases where tissue damage is related to cell death. 
Candidate drugs with established clinical safety are 
available for testing in posttraumatic arthritis.
Cytokine inhibitors, anti-infl  ammatory cytokines
IL-1 inhibition, mainly through the use of IL-1Ra, is 
therapeutically eﬀ  ective in animal models of OA [66,67], 
and preliminary observations from a clinical trial in 
patients with OA suggest symptom-modifying activity 
[67]. In antigen-induced arthritis in rabbits, IL-1Ra also 
had a profound antiﬁ  brotic eﬀ  ect [68]. In this model, the 
synovial ﬁ  brosis was not only halted by administration of 
IL-1Ra but it was reversed [16]. Diacerhein, which inter-
feres with the inﬂ  ammatory and catabolic eﬀ  ects of IL-1, 
provided nearly complete protection in impact models 
[69]. TNFα inhibition by subcutaneous injection of a 
soluble TNF receptor fusion protein showed disease-
modifying activity in the anterior cruciate ligament 
transection model of posttraumatic arthritis in rats [70].
Th   e anti-inﬂammatory cytokine IL-10 has a spectrum 
of chondroprotective activities in chondrocytes. It stimu-
lates collagen type II and proteoglycan expression, 
inhibits MMP, proinﬂammatory cytokine or nitric oxide 
expression and protects against chondrocyte apoptosis 
(reviewed in [71]). IL-10 has also been therapeutically 
eﬀ  ective in an experimental animal model of early OA 
[72]. Th  e chondroprotective potential of IL-4 has been 
demonstrated recently [73]. Th  ese observations suggest 
therapeutic potential of anti-inﬂammatory cytokines in 
posttraumatic cartilage damage [74].
Growth factors
Bone morphogenetic proteins (BMPs) are potent stimuli 
of mesenchymal cell diﬀ   erentiation and extracellular 
matrix formation. BMP-7, also termed osteogenic protein-1, 
has been studied extensively in vitro as well as in animal 
models, and results suggest that BMP-7 may be a candi-
date as a disease-modifying OA drug and also for post-
traumatic arthritis. Unlike transforming growth factor 
beta and other BMPs, BMP-7 upregulates chondro  cyte 
metabolism and protein synthesis without creating 
uncontrolled cell proliferation and formation of osteo-
phytes. BMP-7 prevents chondrocyte catabolism induced 
by IL-1, ﬁ  bronectin fragments or hyaluronan hexasaccha-
rides. BMP-7 has synergistic anabolic eﬀ  ects with other 
growth factors such as insulin-like growth factor-1, 
which in addition to its anabolic eﬀ   ect acts as a cell 
survival factor (reviewed in [75]). Insulin-like growth 
factor-1 has chondroprotective activity in various animal 
models [76]. In acute chondral defect models in the dog 
[77] and goat [78], BMP-7 regenerated articular cartilage, 
increased repair tissue formation and improved inte-
grative repair between new cartilage and the surrounding 
articular surface.
Fibroblast growth factors (FGFs) are important 
regulators of cartilage development and homeostasis 
[79]. FGF-2 can stimulate cartilage repair responses [80], 
but its potent mitogenic eﬀ  ects may lead to chondrocyte 
cluster formation and poor extracellular matrix due to a 
relatively low level of type II collagen [79]. In a rabbit 
anterior cruciate ligament transection model, however, 
sustained release formulations of FGF-2 reduced OA 
severity [81]. FGF-18 has anabolic eﬀ  ects on chondro-
cytes and chondroprogenitor cells, and stimulates cell 
proliferation and type II collagen production [82]. In a rat 
meniscal tear model of OA, intraarticular FGF-18 
injections induced a remarkable formation of new carti-
lage and reduced the severity of the experimental lesions 
[83]. FGF-18 and BMP-7 are currently in clinical 
evaluation in patients with established OA.
Inhibitors of extracellular matrix-degrading 
enzymes
A large number of matrix-degrading enzymes – including 
MMPs, aggrecanases or cathepsins – are involved in 
cartilage matrix destruction in OA, and inhibitors have 
been tested extensively in OA animal models. Several 
MMP inhibitors have been evaluated in clinical trials in 
patients with established OA, and failed either because of 
adverse events or lack of eﬃ   cacy.  Th  e most common 
adverse event was termed musculoskeletal syndrome – 
ﬁ  brotic lesions due to interference of the inhibitors with 
normal collagen turnover [52]. Th   is may not represent a 
major risk if such drugs are administered intraarticularly 
or for short periods of time, for example, to limit the 
Lotz Arthritis Research & Therapy 2010, 12:211 
http://arthritis-research.com/content/12/3/211
Page 5 of 9irreversible collagen degradation in the ﬁ  rst few months 
after injury. Enzyme inhibitors have not been tested in 
single-impact animal models, but in cartilage explants a 
MMP inhibitor reduced GAG loss between 1 and 7 days 
post injury [14].
Antioxidants
Traumatic cartilage and joint injury is associated with 
increased production of reactive oxidant species and 
reduced antioxidant defenses, and this imbalance contri-
butes to cell death and degradation of extracellular matrix 
[84]. Chondrocyte death induced by mechanical injury 
was reduced by antioxidants such as the superoxide 
dismutase mimic Mn(III)porphyrin [85], vitamin E and N-
acetylcysteine [86]. Moreover, N-acetylcysteine treatment 
signiﬁ  cantly improved proteoglycan content at the impact 
sites [87]. Brief exposure to free radical scavengers could 
thus signiﬁ   cantly improve chondrocyte viability and 
protect against extracellular matrix damage following joint 
injury.
Aminosugars
Glucosamine is being used by a large number of OA 
patients but discussion of its eﬃ   cacy and mechanism of 
action after oral administration continues. High concen-
trations of glucosamine and related aminosugars, how-
ever, have anabolic and anti-inﬂ  ammatory  eﬀ  ects  on 
chondrocytes and other joint tissue cells [88]. Since such 
high concentrations in joints can presumably not be 
attained after oral administration, intraarticular injec-
tions may represent a feasible and eﬀ  ective approach. 
Among the various aminosugars that have been tested, 
N-acetylglucosamine has a superior spec  trum of 
activities  in vitro [89]. Intraarticular injection of N-
acetylglucosamine was also eﬀ  ective in an animal model 
of OA [90].
Joint lubricants
Hyaluronan and lubricin are important lubricants of the 
cartilage surfaces. Lubricin concentrations in synovial 
ﬂ  uid are reduced in patients with traumatic arthritis, due 
to enzymatic degradation and suppression of its synthesis 
by inﬂ  ammatory cytokines [11,91]. In rats with meniscal 
tear-induced OA, intraarticular injections of recombinant 
lubricin resulted in disease-modifying, chondroprotective 
eﬀ  ects [92]. Similar to lubricin, hyaluronan is degraded in 
inﬂ   amed joints and there are numerous reports of 
chondroprotective activities in experimental models of 
OA [93]. Interestingly, both lubricin and hyaluronan have 
activities beyond lubrication that may be beneﬁ  cial in the 
setting of posttraumatic arthritis.
Conclusion
OA is the most common form of joint disease aﬀ  ecting a 
patient population that is heterogeneous with regard to 
risk factors and stage of the disease. Disease-modifying 
OA therapies are presently not available. Approximately 
50% of patients with traumatic joint injury develop OA 
and represent a subset of OA that is readily identiﬁ  ed and 
accounts for approximately 12% of all OA cases. Unmet 
needs exist to address the acute posttraumatic inﬂ  am  ma-
tion and to prevent or delay the development of OA. 
Research on experimental models of posttraumatic OA 
and clinical research has led to the elucidation of patho-
genesis pathways. Th   e ideal therapy must be multi-varied 
and include positive eﬀ  ects on chondrocyte metabolism 
and stimulation of intrinsic repair while inhibiting 
catabolic pathways that lead to chondrocyte death and 
matrix loss. A series of molecular targets and drug 
candidates have been identiﬁ  ed, and many of these drug 
candidates were eﬀ  ective in animal models of joint injury 
and OA (Table 2).
Th  e current challenge and opportunity is in the 
translation of this information into eﬀ  ective  therapies 
(Table 3). Th   e major challenge is the long time interval, 
ranging from 5 to 15 years, between joint trauma and 
OA-like joint pathology in humans as detected on 
radiographs or magnetic resonance imaging. Since it is 
not feasible to conduct clinical trials of such duration, 
any therapy to be introduced into clinical use will thus 
Table 2. Potential targets and drugs for pharmacological intervention in posttraumatic arthritis
Target Drugs  References
Caspases  Small molecule inhibitors  [59,60,63,64]
Proinfl  ammatory cytokines (TNFα, IL-1, IL-6)  Neutralizing antibodies, IL-converting enzyme, TACE inhibitors  [66-70]
Cartilage repair  Growth factors (BMP-7, FGF-2, FGF-18, IGF-1)  [75-83]
Matrix-degrading enzymes (matrix metalloproteinases,   Small-molecule inhibitors, TIMP  [14]
aggrecanases, cysteine-dependent cathepsins, 
neutrophil-derived enzymes)
Oxygen radicals  SOD, SOD mimetics  [84-87]
Lubricant defi  ciency  Lubricin, hyaluronan  [92,93]
Anti-infl  ammatory cytokines    [71-74]
SOD, superoxide dismutase; TACE, TNFα converting enzyme; TIMP, tissue inhibitors of metalloproteinases.
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surrogate markers, such as biochemical markers that 
predict or correlate with the progression of cartilage and 
joint damage. Although candidate markers have been 
identiﬁ  ed, they need further validation. A need also exists 
for therapies that address the acute joint inﬂ  ammation 
and improve subjective symptoms such as pain, stiﬀ  ness 
and joint dysfunction during the ﬁ  rst 2 to 3 months after 
injury. Clinical trial design for such studies is facilitated 
by the availability of established endpoints for joint pain, 
function and inﬂ  ammation. Based on the notion that the 
original lesion expands rapidly during this time, there is 
an opportunity to simultaneously address symptoms and 
limit lesion expansion.
We propose, as a near-term approach, interventions 
that should be tested as soon as possible after joint 
trauma with primary objectives to reduce pain and 
inﬂ  ammation and with secondary objectives to improve 
biomarkers of joint destruction. Such therapies can be 
administered as injections into the aﬀ  ected joints, and 
have advantages of reduced risk for systemic adverse 
events and reaching high drug levels at the target tissues. 
Formulation technologies are available to extend intra-
articular retention and thus limit the number of 
injections [94]. Several drug candidates have already been 
tested extensively in preclinical models, and some 
candidates have already been in human clinical trials for 
established OA or other indications.
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